American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Instagram Outage Disrupts Thousands of U.S. Users 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2017 financial results and a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 17334187.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
